Optimization of the Primary Therapy for Patients With Hodgkin's Disease and Evaluation of PET
Status:
Unknown status
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
Prognosis of patients with Hodgkin´s lymphoma (HL) has been improved significantly over the
last decade. Therefore, the impact of treatment associated long-term toxicities and late
effects such as second cancers increased. The purpose of this prospective multicenter trial
is to show the feasibility of the treatment with ABVD alone in patients with limited stage
(HL1) and intermediate stage (HL2) disease and of an intensified etoposide-free chemotherapy
regimen for patients with advanced disease (HL3) including 18F-FDG-PET evaluation.